Memory, executive, and multidomain subtle cognitive impairment

Clinical and biomarker findings

Jon B. Toledo, Maria Bjerke, Kewei Chen, Martin Rozycki, Clifford R. Jack, Michael W. Weiner, Steven E. Arnold, Eric M. Reiman, Christos Davatzikos, Leslie M. Shaw, John Q. Trojanowski

Research output: Contribution to journalArticle

Abstract

Objective: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. Methods: We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants. Results: Using a stringent cutoff (fifth percentile), 27.6% of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively. Conclusions: Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) patternbased analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment.

Original languageEnglish (US)
Pages (from-to)144-153
Number of pages10
JournalNeurology
Volume85
Issue number2
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

Biomarkers
Alzheimer Disease
Neuroimaging
Atrophy
Dementia
Cognitive Dysfunction
Brain

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Toledo, J. B., Bjerke, M., Chen, K., Rozycki, M., Jack, C. R., Weiner, M. W., ... Trojanowski, J. Q. (2015). Memory, executive, and multidomain subtle cognitive impairment: Clinical and biomarker findings. Neurology, 85(2), 144-153. https://doi.org/10.1212/WNL.0000000000001738

Memory, executive, and multidomain subtle cognitive impairment : Clinical and biomarker findings. / Toledo, Jon B.; Bjerke, Maria; Chen, Kewei; Rozycki, Martin; Jack, Clifford R.; Weiner, Michael W.; Arnold, Steven E.; Reiman, Eric M.; Davatzikos, Christos; Shaw, Leslie M.; Trojanowski, John Q.

In: Neurology, Vol. 85, No. 2, 01.07.2015, p. 144-153.

Research output: Contribution to journalArticle

Toledo, JB, Bjerke, M, Chen, K, Rozycki, M, Jack, CR, Weiner, MW, Arnold, SE, Reiman, EM, Davatzikos, C, Shaw, LM & Trojanowski, JQ 2015, 'Memory, executive, and multidomain subtle cognitive impairment: Clinical and biomarker findings', Neurology, vol. 85, no. 2, pp. 144-153. https://doi.org/10.1212/WNL.0000000000001738
Toledo, Jon B. ; Bjerke, Maria ; Chen, Kewei ; Rozycki, Martin ; Jack, Clifford R. ; Weiner, Michael W. ; Arnold, Steven E. ; Reiman, Eric M. ; Davatzikos, Christos ; Shaw, Leslie M. ; Trojanowski, John Q. / Memory, executive, and multidomain subtle cognitive impairment : Clinical and biomarker findings. In: Neurology. 2015 ; Vol. 85, No. 2. pp. 144-153.
@article{4fc907c615dc4c70838a273ffd44d41e,
title = "Memory, executive, and multidomain subtle cognitive impairment: Clinical and biomarker findings",
abstract = "Objective: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. Methods: We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants. Results: Using a stringent cutoff (fifth percentile), 27.6{\%} of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively. Conclusions: Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) patternbased analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment.",
author = "Toledo, {Jon B.} and Maria Bjerke and Kewei Chen and Martin Rozycki and Jack, {Clifford R.} and Weiner, {Michael W.} and Arnold, {Steven E.} and Reiman, {Eric M.} and Christos Davatzikos and Shaw, {Leslie M.} and Trojanowski, {John Q.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1212/WNL.0000000000001738",
language = "English (US)",
volume = "85",
pages = "144--153",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Memory, executive, and multidomain subtle cognitive impairment

T2 - Clinical and biomarker findings

AU - Toledo, Jon B.

AU - Bjerke, Maria

AU - Chen, Kewei

AU - Rozycki, Martin

AU - Jack, Clifford R.

AU - Weiner, Michael W.

AU - Arnold, Steven E.

AU - Reiman, Eric M.

AU - Davatzikos, Christos

AU - Shaw, Leslie M.

AU - Trojanowski, John Q.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Objective: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. Methods: We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants. Results: Using a stringent cutoff (fifth percentile), 27.6% of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively. Conclusions: Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) patternbased analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment.

AB - Objective: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. Methods: We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants. Results: Using a stringent cutoff (fifth percentile), 27.6% of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively. Conclusions: Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) patternbased analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment.

UR - http://www.scopus.com/inward/record.url?scp=84942744439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942744439&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000001738

DO - 10.1212/WNL.0000000000001738

M3 - Article

VL - 85

SP - 144

EP - 153

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -